Contract Manufacturing Services Market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis – KYT24

Driven by a robust and growing pipeline of stem cell therapies, the demand for development and manufacturing services for such advanced product candidates is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the Stem Cell Contract Manufacturing Market, 2019-2030 report to its list of offerings.

Owing to a highly regulated production environment and the need for state-of-the-art technologies and equipment, it is difficult for innovators to establish in-house expertise for the large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers are increasingly relying on contract manufacturing organizations (CMOs) for their product development and manufacturing needs.

To order this 300+ page report, which features 120+ figures and 145+ tables, please visit this link

Over 80 CMOs presently claim to provide manufacturing services for stem cells therapies The market landscape is fragmented, featuring a mix of companies of all sizes; however, small and mid-sized companies represent 70% of the overall number of industry stakeholders. It is worth highlighting that over 50% of the CMOs claim to be capable of accommodating both clinical and commercial scales of operation.

100+ strategic alliances have been inked since 2015 In fact, nearly 60% of the abovementioned deals were established post 2016. Majority of these agreements were observed to be focused on the manufacturing of various types of stem cells. It is worth highlighting that the maximum number of partnerships related to stem cell therapies were reported in 2018.

More than 80,000+ patients were reported to have been enrolled in stem cell therapy related trials, since 2010 As a result, the manufacturing demand for such therapies can be anticipated to grow significantly over the next decade. The report features detailed projections of the future clinical and commercial demand for stem cell manufacturing, based on parameters, such as target patient population, dosing frequency, dose strength, source of stem cells, type of stem cells and key geographies.

Currently, there are more than 100 facilities dedicated to stem cell manufacturing The maximum share of the installed capacity belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies. The report provides a detailed capacity analysis, taking into consideration the reported manufacturing capacities of industry stakeholders, and offering estimates on the distribution of the global contract manufacturing capacity for stem cell therapies, by company size, scale of operation and geography.

By 2030, North America and Europe are anticipated to capture over 70% of the market share Overall, the market is anticipated to witness an annualized growth rate of more than 20% over the next decade. In the long-term, the opportunity is expected to be well distributed across key stakeholder companies, which offer services for a diverse range of allogenic and autologous stem cell therapies.

To request a sample copy / brochure of this report, please visit this link

The USD 2.5 billion (by 2030) financial opportunity within the stem cells contract manufacturing market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom the contract manufacturing opportunity related to stem cell therapies can be expected to witness substantial growth due to the rising demand for regenerative medicine across a number of therapeutic areas. The report includes detailed transcripts of discussions held with the following experts:

The research covers detailed profiles of key players (illustrative list provided below) from across key global markets (North America, Europe and Asia-Pacific); each profile provides an overview of the company, information on its service portfolio, manufacturing facilities, financial performance (if available), details on recent developments, as well as an informed future outlook.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cell-therapy-contract-manufacturing-market-2019-2030/271.html

or email [emailprotected]

Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [emailprotected]

View post:
Contract Manufacturing Services Market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis - KYT24

Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast…

The latest market report published by Reports and Data, titled Global Stem Cells Market, presents an accurate analysis of the estimated market size, share, revenue, and sales & distribution networks of the global Stem Cells market over the forecast period. The report offers an exhaustive overview of the market, along with a precise summary of the markets leading regions. Our team of analysts has studied the existing competitive landscape of the market inside out, focusing on the leading companies and their business expansion strategies. The report ends with conclusive data offering useful insights into the market growth on both regional and global levels.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Thermo Fisher Scientific, Agilent Technologies, Illumina, Inc., Qiagen, Oxford Nanopore Technologies, Eurofins Scientific, F. Hoffmann-La Roche, Danaher Corporation, Bio-Rad Laboratories, and GE Healthcare

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2981

The report draws the focus of the reader on the grave impact of the ongoing COVID-19 pandemic on the Stem Cells industry and its vital segments and sub-segments. It elaborates on the adverse effects of the pandemic on the global economic scenario, as well as this particular business sphere. The report takes into account the key influencing factors influencing market performance in the present COVID-19 times. The market has been substantially affected by the pandemic, and significant changes have been observed in the market dynamics and demand trends. The report examines the major financial difficulties brought about by the pandemic and offers a future COVID-19 impact assessment.

The market intelligence study takes the reader through the key parameters of the Stem Cells market, including the strengths and weaknesses of the leading players, using analytical tools like the SWOT analysis and Porters Five Forces analysis. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players.

Product Outlook (Revenue, USD Billion; 2017-2027)

Technology Outlook (Revenue, USD Billion; 2017-2027)

Therapy Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2981

The investigative study further assesses the market on the basis of market reach and consumer base in the key geographical segments. Alongside reviewing the sales network, distribution channels, pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market, the report studies several factors affecting market growth over the forecast period, such as drivers, restraints, limitations, growth prospects, and numerous macro- and micro-economic indicators.

Key Geographies Encompassed in the Report:

Key questions addressed in the report:

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/stem-cells-market

Thank you for reading our report. For further queries regarding the report, please get in touch with us. Our team will ensure your report is customized as per your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Visit link:
Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast...

November 2020: Intramural Papers of the Month – Environmental Factor Newsletter

Intramural Papers

Intramural By Nicholas Alagna, Mimi Huang, Sanya Mehta, Prashant Rai, and Saniya Rattan

Assessing the potential carcinogenicity and toxicity of botanical dietary supplements, such as Ginkgo biloba extract (GbE), in rodent systems is challenging due to the variability in commercially available products. To address this issue, scientists at the NIEHS Divisions of the National Toxicology Program (NTP) and Intramural Research used several analytical chemistry and chemometric techniques to compare the composition of GbE used in recent NTP research with other GbE samples on the market, as well as with the National Institute of Standards and Technology (NIST) GbE standard reference materials. Their results suggested that a simple analysis for the presence, absence, or amount of compounds unique to GbE would be adequate to determine the authenticity of a GbE sample.

The scientists conducted chemometric analysis of chromatographic and spectrophotometric data to determine that GbE used in rodent experiments was most similar to the NIST reference materials and two unfinished products, as well as finished commercial products containing an authentic GbE extract, based on their constituent profiles. Because the team found its particular GbE was representative of other high quality GbE products, the results of the NTP carcinogenicity and toxicity study could be more broadly applied to other similar GbE products on the market. (NA)

Citation:Collins BJ, Kerns SP, Aillon K, Mueller G, Rider CV, DeRose EF, London RE, Harnly JM, Waidyanatha S. 2020. Comparison of phytochemical composition of Ginkgo biloba extracts using a combination of non-targeted and targeted analytical approaches. Anal Bioanal Chem 412(25):67896809.

Researchers from NIEHS and its Division of NTP found that subtle changes to mitochondrial function led to long-lasting epigenomic effects in the mouse. Scientists identified that mitochondrial inhibition during early development persistently altered DNA methylation and liver gene expression throughout the life of the mouse. The long-term effects observed in this study shed light on potential mechanisms involved with health outcomes under the developmental origins of health and disease paradigm.

To assess the effects of subtle alteration of mitochondrial function on epigenetics, researchers used the viable yellow agouti mouse, Avy, which reveals DNA methylation changes through changes in the coat color of the animals. Mice born from mothers fed with a mitochondrial inhibitor, rotenone, solely during gestation and lactation, showed an altered coat color distribution. The mice also showed altered DNA methylation and gene expression patterns in the liver, effects that were observed up to 18 months after rotenone exposure had ceased. Finally, the animals showed that prenatal rotenone exposure led to altered mitochondrial and antioxidant function later in life, demonstrating that early exposure influenced long-term health outcomes.

This study places mitochondria as players in controlling gene expression through epigenetic mechanisms and highlights how environmental toxicants could influence long-term health outcomes. (SR)

Citation:Lozoya OA, Xu F, Grenet D, Wang T, Grimm SA, Godfrey V, Waidyanatha S, Woychik RP, Santos JH. 2020. Single nucleotide resolution analysis reveals pervasive, long-lasting DNA methylation changes by developmental exposure to a mitochondrial toxicant. Cell Rep 32(11):108131.

To uncover novel deletion patterns in mitochondrial DNA (mtDNA), NIEHS researchers and their collaborators developed LostArc, an ultrasensitive method for quantifying deletions in circular mtDNA molecules. The team used the technique to reveal links between mitochondrial DNA replication, aging, and mitochondrial disease.

A mutation in POLG, a nuclear gene responsible for maintaining the mitochondrial genome, is known to be the most common cause of mitochondrial disease, a condition where the mitochondria fail to produce enough energy for the body to function properly.

The scientists analyzed mtDNA from skeletal muscle biopsies of 41 patients with mitochondrial disease with wild-type (WT) and mutated POLG. They used LostArc to detect loss of mtDNA segments by mapping split-reads in the samples to a normal mtDNA reference. Thirty-five million deletion segments were detected in the biopsies. They spanned more than 470,000 unique segments, 99% of which were novel. The scientists also found that ablation, or loss of mtDNA segments to deletion, significantly increased with age. Mutated POLG samples had higher ablation levels than WT. These changes in mtDNA ablation help explain some of the muscular symptoms of aging and disease. The additional potential applications of LostArc include genetic screening, diagnostic applications, and medical forensics. (SM)

Citation:Lujan SA, Longley MJ, Humble MH, Lavender CA, Burkholder A, Blakely EL, Alston CL, Gorman GS, Turnbull DM, McFarland R, Taylor RW, Kunkel TA, Copeland WC. 2020. Ultrasensitive deletion detection links mitochondrial DNA replication, disease, and aging. Genome Biol 21(1):248.

The cellular signaling molecule InsP7 can modify the abundance of cytosolic, membrane-less condensates called P-bodies through a new epitranscriptomic process identified by NIEHS researchers and their collaborators. P-bodies contain structurally and metabolically stabilized mRNAs, which can subsequently be released to drive protein expression in response to environmental stress. The mRNA release can sometimes promote protein expression in a specific location within the cell and can also direct stem cell differentiation. The possible role of P-bodies in aging and neurodegenerative disease suggests potential therapeutic implications of these findings.

The relationship between InsP7 and P-bodies is centered on the enzyme NUDT3, a phosphate-cleaving enzyme that not only metabolizes InsP7 but also removes the structurally stabilizing cap from the mRNA. By competing with NUDT3-catalyzed mRNA cap removal, InsP7 increases mRNA transcript levels and P-body abundance. It appears that de-capping enzymes like NUDT3 each have specific mRNA targets, so this regulatory ability of InsP7 is likely specific to NUDT3. Thus, the authors study is a significant step forward in the understanding of how the cell can selectively regulate the fate and function of specific mRNA transcripts. (MH)

Citation:Sahu S, Wang Z, Jiao X, Gu C, Jork N, Wittwer C, Li X, Hostachy S, Fiedler D, Wang H, Jessen HJ, Kiledjian M, Shears SB. 2020. InsP7 is a small-molecule regulator of NUDT3-mediated nRNA decapping and processing-body dynamics. Proc Natl Acad Sci U S A 117(32):1924519253.

NIEHS scientists and their collaborators reported that spatial protein-DNA interaction between transcription factors and their specific binding sites in the genome is a key step to initiating the transcription of genetic code. The study was conducted on a transcription factor called GATA3, which can bind directly to the condensed structural units of the human genome, called nucleosomes, and drive transcription of genes necessary for cellular reprogramming and differentiation.

The study used high-resolution mapping to reveal that GATA3 binding near the central axis of the nucleosome coil was associated with remodeling of local DNA structure to facilitate a productive reading of genetic code. This binding was found to be independent of the genetic sequence of nucleosomes. The study used an in vitro model of a nucleosome and cryoelectron microscopy and found that nonproductive GATA3 binding, without any structural changes to the nucleosome, occurred efficiently at the periphery of the nucleosome coil.

Binding of a transcription factor, such as GATA3, in a specific spatial arrangement on the nucleosome surface affects the local genomic scaffolds and could determine the overall outcome of such binding in gene regulation. (PR)

Citation:Tanaka H, Takizawa Y, Takaku M, Kato D, Kumagawa Y, Grimm SA, Wade PA, Kurumizaka H. 2020. Interaction of the pioneer transcription factor GATA3 with nucleosomes. Nat Commun 11(1):4136. (Story)

(Nicholas Alagna is an Intramural Research Training Award [IRTA] fellow in the NIEHS Mechanisms of Mutation Group. Mimi Huang, Ph.D., is an IRTA fellow in the Division of the National Toxicology Program Systems Toxicology Group. Sanya Mehta is an IRTA postbaccalaureate fellow in the NIEHS Matrix Biology Group. Prashant Rai, Ph.D., is a visiting fellow in the NIEHS Clinical Investigation of Host Defense Group. Saniya Rattan, Ph.D., is an IRTA fellow in the NIEHS Reproductive Developmental Biology Group.)

Follow this link:
November 2020: Intramural Papers of the Month - Environmental Factor Newsletter